TFF Pharmaceuticals Makes Available Phase 2 Data From Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection Presented At The Recent ISHLT Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced positive Phase 2 trial data for Tacrolimus Inhalation Powder (TFF TAC) for lung transplant rejection prevention, presented at the ISHLT Annual Meeting. The data show TFF TAC prevents rejection with lower doses and systemic exposures than oral tacrolimus, and normalizes rejection-related gene expressions. The company plans to advance the program into potentially registrational testing.
April 29, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TFF Pharmaceuticals revealed promising Phase 2 data for TFF TAC, indicating potential for improved efficacy and safety in lung transplant rejection prevention.
The positive Phase 2 trial results for TFF TAC suggest a significant advancement in lung transplant medicine, potentially improving patient outcomes with lower systemic toxicities. This innovation aligns with TFF Pharmaceuticals' focus on developing drug products based on its patented Thin Film Freezing technology. The announcement could lead to increased investor interest and positive sentiment towards TFFP's stock in the short term, as it demonstrates progress in a critical clinical program and potential market advantage.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100